NYSE:BSX - New York Stock Exchange, Inc. - US1011371077 - Common Stock - Currency: USD
106.54
-0.12 (-0.11%)
The current stock price of BSX is 106.54 USD. In the past month the price increased by 12.09%. In the past year, price increased by 40.87%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.28 | 234.48B | ||
ISRG | INTUITIVE SURGICAL INC | 72.93 | 199.70B | ||
SYK | STRYKER CORP | 31.09 | 148.69B | ||
MDT | MEDTRONIC PLC | 16.17 | 110.77B | ||
BDX | BECTON DICKINSON AND CO | 12.54 | 50.73B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.93 | 45.76B | ||
IDXX | IDEXX LABORATORIES INC | 45.36 | 41.91B | ||
RMD | RESMED INC | 27.33 | 36.38B | ||
DXCM | DEXCOM INC | 52.93 | 34.25B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.62 | 32.90B | ||
STE | STERIS PLC | 26.82 | 24.61B | ||
PODD | INSULET CORP | 90.71 | 23.04B |
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752 US
CEO: Michael F. Mahoney
Employees: 53000
Phone: 15086834000
The current stock price of BSX is 106.54 USD. The price decreased by -0.11% in the last trading session.
The exchange symbol of BOSTON SCIENTIFIC CORP is BSX and it is listed on the New York Stock Exchange, Inc. exchange.
BSX stock is listed on the New York Stock Exchange, Inc. exchange.
38 analysts have analysed BSX and the average price target is 120.09 USD. This implies a price increase of 12.72% is expected in the next year compared to the current price of 106.54. Check the BOSTON SCIENTIFIC CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BOSTON SCIENTIFIC CORP (BSX) has a market capitalization of 157.58B USD. This makes BSX a Large Cap stock.
BOSTON SCIENTIFIC CORP (BSX) currently has 53000 employees.
BOSTON SCIENTIFIC CORP (BSX) has a support level at 106.18 and a resistance level at 106.55. Check the full technical report for a detailed analysis of BSX support and resistance levels.
The Revenue of BOSTON SCIENTIFIC CORP (BSX) is expected to grow by 17.42% in the next year. Check the estimates tab for more information on the BSX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BSX does not pay a dividend.
BOSTON SCIENTIFIC CORP (BSX) will report earnings on 2025-07-22, before the market open.
The PE ratio for BOSTON SCIENTIFIC CORP (BSX) is 39.46. This is based on the reported non-GAAP earnings per share of 2.7 and the current share price of 106.54 USD. Check the full fundamental report for a full analysis of the valuation metrics for BSX.
The outstanding short interest for BOSTON SCIENTIFIC CORP (BSX) is 1.07% of its float. Check the ownership tab for more information on the BSX short interest.
ChartMill assigns a technical rating of 10 / 10 to BSX. When comparing the yearly performance of all stocks, BSX is one of the better performing stocks in the market, outperforming 89.44% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to BSX. BSX scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months BSX reported a non-GAAP Earnings per Share(EPS) of 2.7. The EPS increased by 26.17% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 11.58% | ||
ROA | 5.06% | ||
ROE | 9.15% | ||
Debt/Equity | 0.47 |
ChartMill assigns a Buy % Consensus number of 84% to BSX. The Buy consensus is the average rating of analysts ratings from 38 analysts.
For the next year, analysts expect an EPS growth of 17.26% and a revenue growth 17.42% for BSX